Search | Clinical Trials Finder

Conditions: Diabetes Mellitus, Type 1
Interventions: Gan & Lee Insulin Glargine Injection, Lantus®; Biological
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Birmingham, Alabama • Fresno, California • Newport Beach, California + 41 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 85
States / cities: Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year to 6 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 8
States / cities: Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2963016, LANTUS®, Oral Antihyperglycemic Medication; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more

Conditions: Type 2 Diabetes
Interventions: Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID, Insulin Glargine (Mandatory background drug), Metformin (Background drug); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 46
States / cities: Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin Aspart SAR341402, Insulin Aspart, Insulin glargine U100; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 33
States / cities: Concord, California • Temecula, California • Ventura, California + 30 more

Conditions: AMI
Interventions: Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 13
States / cities: Tucson, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 9 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 12,537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type 1 Diabetes Mellitus
Interventions: SAR342434, Humalog, Insulin glargine HOE901; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 47
States / cities: Tucson, Arizona • Bell Gardens, California • Chula Vista, California + 36 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, 75% insulin lispro protamine suspension and 25 % insulin lispro injection; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type 2 Diabetes
Interventions: Exenatide, Glargine, Rapid-acting insulin analogs; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 19
States / cities: Escondido, California • La Jolla, California • San Mateo, California + 16 more

Conditions: Type 2 Diabetes
Interventions: Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 108
States / cities: Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Glulisine, Insulin Glargine, Premixed Insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes, Type 1
Interventions: Technosphere Insulin, Insulin glargine, Insulin lispro; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 20
States / cities: Huntington Beach, California • La Jolla, California • San Mateo, California + 14 more

Conditions: Diabetes Mellitus
Interventions: Lantus (insulin glargine [rDNA origin] injection), Metformin, Glyburide, Thiazolidinedione; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type 2 Diabetes Mellitus
Interventions: HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 117
States / cities: Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more

Conditions: Type 1 Diabetes
Interventions: Mylan's insulin glargine, Lantus®; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 72
States / cities: Bell Gardens, California • Fresno, California • Greenbrae, California + 64 more

Conditions: Type 2 Diabetes Mellitus
Interventions: pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir]); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 37
States / cities: Northport, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more

Conditions: Type 2 Diabetes
Interventions: Liraglutide + OADs, Glargine + OADs; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 5
States / cities: Miami, Florida • Atlanta, Georgia • New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 929 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 74
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Afrezza, Rapid-acting Insulin Analog, Basal Insulin; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 39
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 35 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin Degludec, Insulin Glargine, TRESIBA® FLEXTOUCH®, LANTUS® SOLOSTAR® INSULIN PEN; Drug · Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Santa Barbara, California • Honolulu, Hawaii

Search by objective public record fields.

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Insulin Glargine "All to Target" Trial

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

Liraglutide Hospital Discharge Trial

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Afrezza® INHALE-1 Study in Pediatrics

Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.